New stem cell combo aims to stop lymphoma from spreading to the brain

NCT ID NCT07481669

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a modified stem cell transplant regimen for lymphoma patients at high risk of the cancer spreading to the brain. About 45 adults who have already responded to initial treatment will receive high-dose chemotherapy with thiotepa, etoposide, cytarabine, and melphalan, followed by a transplant of their own stem cells. The goal is to see if this approach can improve how long patients live without the cancer getting worse, while being safer and more affordable than current options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA PATIENTS WITH HIGH-RISK OF CENTRAL NERVOUS SYSTEM RELAPSE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
RECRUITING

Hangzhou, Zhejiang, 310000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••